Literature DB >> 16687313

Circadian uses of melatonin in humans.

Alfred J Lewy1, Jonathan Emens, Angela Jackman, Krista Yuhas.   

Abstract

Melatonin in humans can be an independent or dependent variable. Measurement of endogenous melatonin levels under dim-light conditions, particularly the dim-light melatonin onset (DLMO), has received increasing attention among researchers, and for clinicians it may soon become a convenient test that can be done at home using saliva collections in the evening, without interfering with sleep. Melatonin, even at low physiological doses, can cause advances (shifts to an earlier time) or delays (shifts to a later time) depending on when it is administered on its phase-response curve (in most sighted people, these times are approximately in the p.m. and in the a.m., respectively). Although both bright light and melatonin can be used separately or together in the treatment of circadian phase disorders in sighted people-such as advanced and delayed sleep phase syndromes, jet lag, shift-work maladaptation, and winter depression (seasonal affective disorder, or SAD)-melatonin is the treatment of choice in totally blind people. These people provide a unique opportunity to study the human circadian system without the overwhelming effects of ocularly mediated light, thus permitting us to establish that all blind free-runners (BFRs) studied under high resolution appear to have phase-advancing and phase-delaying responses to as yet unidentified zeitgebers (time givers) that are usually too weak to result in entrainment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687313     DOI: 10.1080/07420520500545862

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  23 in total

Review 1.  The management of sleep and circadian disturbance in patients with dementia.

Authors:  Qiuping Pearl Zhou; Lorena Jung; Kathy C Richards
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

2.  Combination of light and melatonin time cues for phase advancing the human circadian clock.

Authors:  Tina M Burke; Rachel R Markwald; Evan D Chinoy; Jesse A Snider; Sara C Bessman; Christopher M Jung; Kenneth P Wright
Journal:  Sleep       Date:  2013-11-01       Impact factor: 5.849

Review 3.  Chronotherapies for Parkinson's disease.

Authors:  Karim Fifel; Aleksandar Videnovic
Journal:  Prog Neurobiol       Date:  2019-01-15       Impact factor: 11.685

4.  Genetic differences in human circadian clock genes among worldwide populations.

Authors:  Christopher M Ciarleglio; Kelli K Ryckman; Stein V Servick; Akiko Hida; Sam Robbins; Nancy Wells; Jennifer Hicks; Sydney A Larson; Joshua P Wiedermann; Krista Carver; Nalo Hamilton; Kenneth K Kidd; Judith R Kidd; Jeffrey R Smith; Jonathan Friedlaender; Douglas G McMahon; Scott M Williams; Marshall L Summar; Carl Hirschie Johnson
Journal:  J Biol Rhythms       Date:  2008-08       Impact factor: 3.182

5.  Circadian phase-shifting effects of repeated ramelteon administration in healthy adults.

Authors:  Gary S Richardson; Phyllis C Zee; Sherry Wang-Weigand; Laura Rodriguez; Xuejun Peng
Journal:  J Clin Sleep Med       Date:  2008-10-15       Impact factor: 4.062

6.  Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT.

Authors:  Ingeborg M van Geijlswijk; Kristiaan B van der Heijden; A C G Egberts; Hubert P L M Korzilius; Marcel G Smits
Journal:  Psychopharmacology (Berl)       Date:  2010-07-29       Impact factor: 4.530

Review 7.  Circadian rhythm disturbances in depression.

Authors:  Anne Germain; David J Kupfer
Journal:  Hum Psychopharmacol       Date:  2008-10       Impact factor: 1.672

Review 8.  Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review.

Authors:  Robert L Sack; Dennis Auckley; R Robert Auger; Mary A Carskadon; Kenneth P Wright; Michael V Vitiello; Irina V Zhdanova
Journal:  Sleep       Date:  2007-11       Impact factor: 5.849

9.  Melatonin and agomelatine for preventing seasonal affective disorder.

Authors:  Barbara Nussbaumer-Streit; Amy Greenblatt; Angela Kaminski-Hartenthaler; Megan G Van Noord; Catherine A Forneris; Laura C Morgan; Bradley N Gaynes; Jörg Wipplinger; Linda J Lux; Dietmar Winkler; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

10.  Melatonin administration reduces inflammatory pain in rats.

Authors:  Gabriela Laste; Isabel Cristina de Macedo; Joanna Ripoll Rozisky; Fernanda Ribeiro da Silva; Wolnei Caumo; Iraci Ls Torres
Journal:  J Pain Res       Date:  2012-09-18       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.